Detail of "133107-64-9"

Reference

Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus

Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Jehle, P.Several substances are used for example 50-99-7 and 133107-64-9 which are their cas registry numbers. M.; Fussgaenger, R. D.; Seibold, A.; Luettke, B.; Boehm, B. O. (Department Internal Medicine II, University Ulm, Ulm D-89081, Germany). International Journal of Clinical Pharmacology and Therapeutics, 34(11), 498-503 (English) 1996 Dustri-Verlag Dr. Karl Feistle. CODEN: ICTHEK. ISSN: 0946-1965. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 14 The effects of the rapid acting human insulin analog insulin Lispro on metabolic control and insulin receptor binding in type II diabetes mellitus were studied. Lispro (26,700 vs. 5600 receptors/monocyte) improved the insulin binding and decreased the blood serum glucose and insulin dose. The quick and pulsatile pharmacokinetic profile of Lispro is concluded to improve glycemia, insulin receptor binding, and insulin resistance in type II diabetes. .

Insulin lispro: its role in the treatment of diabetes mellitus

Insulin lispro: its role in the treatment of diabetes mellitus. Campbell, R. Keith; Campbell, Lance K.; White, John R.Several substances are used for example 133107-64-9 which is its cas registry number. (Coll. Pharm., Washington State Univ., Pullman, WA 99164, USA). Annals of Pharmacotherapy, 30(11), 1263-1271 (English/Spanish) 1996 Harvey Whitney Books Co. CODEN: APHRER. ISSN: 1060-0280. DOCUMENT TYPE: Journal; General Review CA Section: 2 (Mammalian Hormones) A review with 50 refs. The aim of our study is to introduce a rapid-acting human insulin analog, insulin lispro; to review its pharmacol., therapeutics, pharmacokinetics, dosing guidelines, adverse effects, and drug interactions; and to summarize the clin. trials of its efficacy and safety alone and in comparison with regular human insulin in the treatment of diabetes mellitus. Due to a relatively few citations listed in MEDLINE (12 as of Dec. 1995), most of the studies reported were found from abstrs. summarizing the clin. action, adverse effects, or pharmacokinetics of insulin lispro in healthy volunteers or patients with diabetes mellitus. A few of the studies used patients with diabetes mellitus in multicenter, randomized, crossover trials of insulin lispro. All clin. trials that were available prior to submission of this manuscript for publication, including unpublished reports, were reviewed. The human insulin analog, insulin lispro, which is biosynthetically made by inverting the amino acid sequence of human insulin at B-28 and B-29, is more effective than regular human insulin in improving postprandial glucose control. S.c. injections of insulin lispro result in decreased blood glucose peaks following meals and a potential decreased risk of hypoglycemic episodes, including nighttime hypoglycemia in patients with type 1 diabetes. Insulin lispro in comparison with regular human insulin provides equal or slightly better blood glucose control. When compared with s.c. injections of regular human insulin, the peak serum insulin concn. of insulin lispro is three times higher, time to peak is 4.2 times faster, the absorption rate const. is double, and the duration of action is half as long. Insulin lispro is similar to regular human insulin with ref. to dose, toxicity, adverse effects, drug interactions, and immunogenicity. When insulin lispro is mixed with human NPH (isophane) or Lente insulins, insulin lispro should be drawn into the syringe first, mixed with the long-acting insulin, and injected immediately after mixing. Patients using insulin lispro perceive an improvement in their well-being and quality of life due to flexible injection times and less frequent hypoglycemic reactions. Insulin lispro is believed to be suitable for patients using insulin infusion pumps. Insulin lispro is equipotent to human insulin and has a much more rapid onset and shorter duration of action than human insulin does, which may reduce the risk of hypoglycemia. In addn., insulin lispro improves the dosing convenience for patients with diabetes and provides a more natural control of blood glucose concns. Insulin lispro is a useful new agent in the treatment of diabetes mellitus. .